NasdaqGS:ERASBiotechs
What Erasca Stock's Pipeline Data Update Means For Shareholders
Erasca reported that updated monotherapy clinical data for ERAS-0015 and nonclinical combination data with ERAS-4001 for RAS and KRAS-mutant solid tumors were selected for presentation at the 38th EORTC-NCI-AACR Symposium, with management indicating progress toward three potentially registration-enabling trials in pancreatic and lung cancers.
The focus on both a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor highlights Erasca's efforts to...